Cited by 190Psychedelics and Drug StudiesNeurotransmitter Receptor Influence on BehaviorForensic Toxicology and Drug Analysis

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies

McCann, Una D., Eligulashvili, Victoria, Ricaurte, George A.·2000·Neuropsychobiology

DOI 10.1159/000026665

Open this paper in CoChat — free account

Abstract

(±)3,4-Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) is a brain serotonergic neurotoxin in experimental animals, including nonhuman primates. It is also an increasingly popular recreational drug of abuse, and doses of MDMA that are used recreationally overlap with those that produce serotonin (5-HT) neurotoxicity in animals. Studies in human MDMA users probing for evidence of brain serotonergic neurotoxicity indicate that some MDMA users may incur MDMA-related 5-HT neural injury and, possibly, functional sequelae. In particular, MDMA users have selective decrements in cerebrospinal fluid 5-hydroxyindoleacetic acid and brain 5-HT transporters, similar to nonhuman primates with documented MDMA-induced neurotoxicity. Functional abnormalities seen in MDMA users that may be related to 5- HT injury include cognitive deficits, altered sleep architecture, altered neuroendocrine function, altered behavioral responses to 5-HT selective drugs, and increased impulsivity. Additional studies in animals, as well as longitudinal and epidemiological studies in MDMA users, are required to confirm and extend the present data, and to determine whether MDMA users are at increased risk for developing neuropsychiatric illness as they age.

Integrity signals

Registry

Crossref · 10.1159/000026665

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

An inventory for assessing different kinds of hostility.
Buss, A. H., & Durkee, A. (1957) · Journal of Consulting Psychology · doi:10.1037/h0046900 · Cited by 2,614
Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings
McCann, U., Szabò, Z., Scheffel, U., Dannals, R. F., & Ricaurte, G. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04329-3 · Cited by 658
Self-citation
Serotonin function in anxiety
Charney, D. S., Woods, S. W., Goodman, W. K., & Heninger, G. R. (1987) · Psychopharmacology · doi:10.1007/bf00215473 · Cited by 462
Central Serotonin and Impulsive Aggression
Coccaro, E. F. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291769 · Cited by 451
Memory impairment in abstinent MDMA ("Ecstasy") users
Bolla, K. I., McCann, U. D., & Ricaurte, G. A. (1998) · Neurology · doi:10.1212/wnl.51.6.1532 · Cited by 374
Self-citation
Serotonergic Responsivity in Obsessive-Compulsive Disorder
Zohar, J. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800230026006 · Cited by 370
Ecstasy use in Australia: patterns of use and associated harm
Topp, L., Hando, J., Dillon, P., ROCHE, A. M., & Solowij, N. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00002-2 · Cited by 353
Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance
Parrott, A. C., & Lasky, J. (1998) · Psychopharmacology · doi:10.1007/s002130050714 · Cited by 338
Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans
McCann, U. D., Ridenour, A., Shaham, Y., & Ricaurte, G. A. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.15 · Cited by 333
Self-citation
Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study
McCann, U., Mertl, M., Eligulashvili, V., & Ricaurte, G. A. (1999) · Psychopharmacology · doi:10.1007/s002130050967 · Cited by 300
Self-citation

Show all 36 references

Sorted by citations

Cognitive Inflexibility After Prefrontal Serotonin Depletion
Clarke, H. F., Dalley, J. W., Crofts, H. S., Robbins, T. W., & Roberts, A. C. (2004) · Science · doi:10.1126/science.1094987 · Cited by 632
The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.
Kalant, H. (2001) · Europe PMC (PubMed Central) · Cited by 604
Human Pharmacology of MDMA
de la Torre, R., Farré, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J., & Camí, J. (2004) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200404000-00009 · Cited by 459
Gender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360
Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research
Parrott, A. C. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.351 · Cited by 337
Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity
Parrott, A. C. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00711-0 · Cited by 325
Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users
Parrott, A. C., Sisk, E., & Turner, J. J. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(99)00146-5 · Cited by 279
Neurotoxicity of substituted amphetamines: Molecular and cellular mechanisms
Cadet, J. L., Krasnova, I. N., Jayanthi, S., & Lyles, J. (2007) · Neurotoxicity Research · doi:10.1007/bf03033567 · Cited by 271
Serotonin and Human Cognitive Performance
Schmitt, J. A. J., Wingen, M., Ramaekers, J. G., Evers, E. A. T., & Riedel, W. J. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777698909 · Cited by 260
Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy
Parrott, A. C. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105048900 · Cited by 231
Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity
Parrott, A. C. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1712-7 · Cited by 232
Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems
Parrott, A. C., Milani, R. M., Parmar, R., & Turner, J. J. (2001) · Psychopharmacology · doi:10.1007/s002130100897 · Cited by 210
Effects of MDMA on sociability and neural response to social threat and social reward
Bedi, G., Phan, K. L., Angstadt, M., & de Wit, H. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1635-z · Cited by 206
Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB
McCann, U. D., Szabó, Z. R., Seckin, E., Rosenblatt, P., Mathews, W. B., Ravert, H. T., Dannals, R. F., & Ricaurte, G. A. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300736 · Cited by 204
Self-citation
Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms
Lyles, J., & Cadet, J. L. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00173-5 · Cited by 194
Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage?
Gouzoulis‐Mayfrank, E., & Daumann, J. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01314.x · Cited by 191
Therapeutic and adverse actions of serotonin transporter substrates
Rothman, R. B., & Baumann, M. H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00234-6 · Cited by 181
The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview
Gouzoulis‐Mayfrank, E., & Daumann, J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106059939 · Cited by 179
The Role of Oxidative Stress, Metabolic Compromise, and Inflammation in Neuronal Injury Produced by Amphetamine-Related Drugs of Abuse
Yamamoto, B. K., & Raudensky, J. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9121-7 · Cited by 167
Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: A WWW study
Scholey, A. B., Parrott, A. C., Buchanan, T., Heffernan, T., Ling, J., & Rodgers, J. (2004) · Addictive Behaviors · doi:10.1016/j.addbeh.2004.02.022 · Cited by 166
Mental disorders in ecstasy users: a prospective-longitudinal investigation
Lieb, R., Schütz, C. G., Pfister, H., von Sydow, K., & Wïttchen, H. (2002) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00190-4 · Cited by 164
Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users
Parrott, A. C., Buchanan, T., Scholey, A. B., Heffernan, T., Ling, J., & Rodgers, J. (2002) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.415 · Cited by 161
Modulation of Synaptic Plasticity by Antimanic Agents: The Role of AMPA Glutamate Receptor Subunit 1 Synaptic Expression
Du, J., Gray, N. A., Falke, C. A., Chen, W., Yuan, P., Szabo, S. T., Einat, H., & Manji, H. K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1258-04.2004 · Cited by 157
Reinforcing, subjective, and physiological effects of MDMA in humans: A comparison with d-amphetamine and mCPP
Tancer, M., & Johanson, C.-E. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00172-8 · Cited by 153
The health effects of ecstasy: a literature review
Gowing, L., HENRY‐EDWARDS, S. M., Irvine, R. J., & Ali, R. L. (2002) · Drug and Alcohol Review · doi:10.1080/09595230220119363 · Cited by 153
MDMA (3,4-Methylenedioxymethamphetamine) or Ecstasy: The Neuropsychobiological Implications of Taking It at Dances and Raves
Parrott, A. C. (2004) · Neuropsychobiology · doi:10.1159/000080961 · Cited by 152
Human Research on MDMA (3,4-Methylene- dioxymethamphetamine) Neurotoxicity: Cognitive and Behavioural Indices of Change
Parrott, A. C. (2000) · Neuropsychobiology · doi:10.1159/000026666 · Cited by 151
3,4-Methylenedioxymethamphetamine (MDMA) as a Unique Model of Serotonin Receptor Function and Serotonin-Dopamine Interactions
Bankson, M. G., & Cunningham, K. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29607-5 · Cited by 150
Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users
Gouzoulis‐Mayfrank, E., Thimm, B., Rezk, M., Hensen, G., & Daumann, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00114-3 · Cited by 148
MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress
Parrott, A. C. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106063268 · Cited by 139
Modafinil: Preclinical, Clinical, and Post-Marketing Surveillance—A Review of Abuse Liability Issues
Myrick, H., Malcolm, R. J., Taylor, B. R., & LaRowe, S. D. (2004) · Annals of Clinical Psychiatry · doi:10.1080/10401230490453743 · Cited by 137
Recognition and management of complications of new recreational drug use
Ricaurte, G. A., & McCann, U. D. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66737-2 · Cited by 134
Self-citation
Locomotor stimulation produced by 3,4-methylenedioxymethamphetamine (MDMA) is correlated with dialysate levels of serotonin and dopamine in rat brain
Baumann, M. H., Clark, R. D., & Rothman, R. B. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.02.018 · Cited by 135
Differential effects of Ecstasy and cannabis on self‐reports of memory ability: a web‐based study
Rodgers, J., Buchanan, T., Scholey, A. B., Heffernan, T., Ling, J., & Parrott, A. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.345 · Cited by 127
Prepulse Inhibition and Habituation of Acoustic Startle Response in Male MDMA (‘Ecstasy’) Users, Cannabis Users, and Healthy Controls
Quednow, B. B., Kühn, K.-U., Hoenig, K., Maier, W., & Wagner, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300396 · Cited by 116
Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls
Lamers, C. T. J., Bechara, A., Rizzo, M., & Ramaekers, J. G. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106059495 · Cited by 112
Mood disorders and serotonin transporter density in ecstasy users—the influence of long-term abstention, dose, and gender
de Win, M. M. L., Reneman, L., Reitsma, J. B., den Heeten, G. J., Booij, J., & van den Brink, W. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1723-4 · Cited by 107
Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation
Daumann, J., Hensen, G., Thimm, B., Rezk, M., Till, B., & Gouzoulis‐Mayfrank, E. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1719-0 · Cited by 105
3,4-Dihydroxymethamphetamine (HHMA). A Major in Vivo 3,4-methylenedioxymethamphetamine (MDMA) Metabolite in Humans
Segura, M., Ortuño, J., Farré, M., McLure, J. A., Pujadas, M., Pizarro, N., Llebaria, A., Joglar, J., Roset, P. N., Segura, J., et al. (2001) · Chemical Research in Toxicology · doi:10.1021/tx010051p · Cited by 104
Review article: Amphetamines and related drugs of abuse
Greene, S. L., Kerr, F., & Braitberg, G. (2008) · Emergency Medicine Australasia · doi:10.1111/j.1742-6723.2008.01114.x · Cited by 101
Neurotoxicity of amphetamine derivatives is mediated by caspase pathway activation in rat cerebellar granule cells
Jiménez, A., Jordà, E. G., Verdaguer, E., Pubill, D., Sureda, F. X., Canudas, A. M., Escubedo, E., Camarasa, J., Camins, A., & Pallàs, M. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.12.017 · Cited by 100
Content of ecstasy in the Netherlands: 1993–2008
Vogels, N., Brunt, T. M., Rigter, S., Dijk, P. V., Vervaeke, H., & Niesink, R. J. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02707.x · Cited by 95
The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): An evidence-based review
Parrott, A. C. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0703-5 · Cited by 87
Is ecstasy perceived to be safe? A critical survey
Gamma, A., Jerome, L., Liechti, M. E., & Sumnall, H. R. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.08.014 · Cited by 78
Dance Clubbing on MDMA and during Abstinence from Ecstasy/MDMA: Prospective Neuroendocrine and Psychobiological Changes
Parrott, A. C., Lock, J. Z., Conner, A. C., Kissling, C., & Thome, J. (2008) · Neuropsychobiology · doi:10.1159/000147470 · Cited by 77
Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study
Huizink, A. C., Ferdinand, R. F., van der Ende, J., & Verhulst, F. C. (2006) · BMJ · doi:10.1136/bmj.38743.539398.3a · Cited by 77
The loudness dependence of the auditory evoked potential (LDAEP) as anin vivobiomarker of central serotonergic function in humans: rationale, evaluation and review of findings
O’Neill, B. V., Croft, R. J., & Nathan, P. J. (2008) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.940 · Cited by 76
Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users
Daumann, J., Fischermann, T., Heekeren, K., Henke, K., Thron, A. K., & Gouzoulis‐Mayfrank, E. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2002-8 · Cited by 76
Psychological profile of abstinent recreational Ecstasy (MDMA) users and significance of concomitant cannabis use
Daumann, J., Pelz, S., Becker, S., Tuchtenhagen, F., & Gouzoulis‐Mayfrank, E. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.342 · Cited by 76
Drug use practices among MDMA/ecstasy users in Ohio: a latent class analysis
Carlson, R. G., Wang, J., Falck, R. S., & Siegal, H. A. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.01.011 · Cited by 74
MDMA (‘ecstasy’) and other ‘club drugs’
Koesters, S. C., Rogers, P. D., & Rajasingham, C. R. (2002) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(01)00012-8 · Cited by 73
Personality dimensions and psychopathological profiles of Ecstasy users
Dughiero, G., Schifano, F., & Forza, G. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.346 · Cited by 72
A Prospective Cohort Study on Sustained Effects of Low-Dose Ecstasy Use on the Brain in New Ecstasy Users
de Win, M. M. L., Reneman, L., Jager, G., Vlieger, E.-J., Olabarriaga, S. D., Lavini, C., Bisschops, I., Majoie, C. B. L. M., Booij, J., den Heeten, G. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301225 · Cited by 71
Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users
Parrott, A. C., Milani, R. M., Gouzoulis‐Mayfrank, E., & Daumann, J. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0715-7 · Cited by 70
Cortisol and 3,4-Methylenedioxymethamphetamine: Neurohormonal Aspects of Bioenergetic Stress in Ecstasy Users
Parrott, A. C. (2009) · Neuropsychobiology · doi:10.1159/000253551 · Cited by 68
Nitrotyrosine as a marker for peroxynitrite‐induced neurotoxicity: the beginning or the end of the end of dopamine neurons?
Kuhn, D. M., Sakowski, S. A., Sadidi, M., & Geddes, T. J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02346.x · Cited by 66
Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study
Daumann, J., Fimm, B., Willmes, K., Thron, A. K., & Gouzoulis‐Mayfrank, E. (2003) · Cognitive Brain Research · doi:10.1016/s0926-6410(03)00075-2 · Cited by 66
Contribution ???of ???Cytochrome??? P450??2D6??to??3,4-Methylenedioxymethamphetamine Disposition in Humans
Segura, M., Farr, M., Pichini, S., Peir, A. M., Roset, P. N., rez, A. R., Ortu�o, J., Pacifici, R., Zuccaro, P., Segura, J., et al. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544060-00006 · Cited by 65
Perspectives on Zebrafish Models of Hallucinogenic Drugs and Related Psychotropic Compounds
Neelkantan, N., Mikhaylova, A., Stewart, A., Arnold, R., Gjeloshi, V., Kondaveeti, D., Poudel, M. K., & Kalueff, A. V. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400090q · Cited by 67
Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA (“Ecstasy”) and MDA (“Love”)
McNamara, R., Kerans, A., O’Neill, B. V., & Harkin, A. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.08.006 · Cited by 64
Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: Evidence from an 18-month longitudinal functional magnetic resonance imaging study
Daumann, J., Fischermann, T., Heekeren, K., Thron, A. K., & Gouzoulis‐Mayfrank, E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.011 · Cited by 63
Differential Effects of Ecstasy on Short-Term and Working Memory: A Meta-Analysis
Nulsen, C. E., Fox, A. M., & Hammond, G. R. (2010) · Neuropsychology Review · doi:10.1007/s11065-009-9124-z · Cited by 63
The Potential Dangers of Using MDMA for Psychotherapy
Parrott, A. C. (2014) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2014.873690 · Cited by 63
Methamphetamine and MDMA (Ecstasy) Neurotoxicity: 'of Mice and Men'
Itzhak, Y., & Achat‐Mendes, C. (2004) · IUBMB Life · doi:10.1080/15216540410001727699 · Cited by 59
Ecstasy use and self-reported depression, impulsivity, and sensation seeking: a prospective cohort study
de Win, M. M. L., Schilt, T., Reneman, L., Vervaeke, H., Jager, G., Dijkink, S., Booij, J., & van den Brink, W. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106063275 · Cited by 57
Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans
Spitzer, M., Franke, B., Walter, H., Buechler, J., Wunderlich, A. P., Schwab, M. G., Kovar, K., Hermle, L., & Grön, G. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(01)00060-0 · Cited by 57
Electrochemical and spectroscopic characterisation of amphetamine-like drugs: Application to the screening of 3,4-methylenedioxymethamphetamine (MDMA) and its synthetic precursors
Milhazes, N., Martins, P., Uriarte, E., Garrido, J. M. P. J., Calheiros, R., Marques, M. P. M., & Borges, F. (2007) · Analytica Chimica Acta · doi:10.1016/j.aca.2007.06.027 · Cited by 56
Sources of information about MDMA (3,4-methylenedioxymethamphetamine): perceived accuracy, importance, and implications for prevention among young adult users
Falck, R. S., Carlson, R. G., Wang, J., & Siegal, H. A. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2003.11.009 · Cited by 56
Effects of a single dose of 3,4-methylenedioxymethamphetamine on circadian patterns, motor activity and sleep in drug-naive rats and rats previously exposed to MDMA
Balogh, B., Molnár, E., Jakus, R., Quate, L., Olverman, H. J., Kelly, P. A. T., Kántor, S., & Bagdy, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1787-9 · Cited by 55
Methylenedioxymethamphetamine (MDMA) in Psychiatry
Schenk, S., & Newcombe, D. A. L. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000962 · Cited by 53
Effects of (±) 3,4-Methylenedioxymethamphetamine (MDMA) on Sleep and Circadian Rhythms
McCann, U. D., & Ricaurte, G. A. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.214 · Cited by 54
Self-citation
Memory performance in polyvalent MDMA (ecstasy) users who continue or discontinue MDMA use
Gouzoulis‐Mayfrank, E., Fischermann, T., Rezk, M., Thimm, B., Hensen, G., & Daumann, J. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.12.002 · Cited by 52
Influence of CYP2D6 polymorphism on 3,4-methylenedioxymethamphetamine (‘Ecstasy’) cytotoxicity
Carmo, H., Brulport, M., Hermes, M., Oesch, F., Silva, R. V. D. S., Ferreira, L. M., Branco, P. S., de Boer, D., Remião, F., Carvalho, F. D., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000230419.05221.fc · Cited by 50
Multiple molecular and neuropharmacological effects of MDMA (Ecstasy)
Simantov, R. (2003) · Life Sciences · doi:10.1016/j.lfs.2003.08.002 · Cited by 46
Neural correlates of working memory in pure and polyvalent ecstasy (MDMA) users
Daumann, J., Schnitker, R., Weidemann, J., Schnell, K., Thron, A. K., & Gouzoulis‐Mayfrank, E. (2003) · Neuroreport · doi:10.1097/00001756-200310270-00021 · Cited by 44
Disorders of Sodium and Water Balance
Harring, T. R., Deal, N., & Kuo, D. C. (2014) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2014.01.001 · Cited by 43
Hydrothermally synthesized zinc oxide nanorods incorporated on lab-on-paper device for electrochemical detection of recreational drug
Narang, J., Singhal, C., Khanuja, M., Mathur, A. K., Jain, A. K., & Pundir, C. S. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1381614 · Cited by 42
Targeting the 5-HT system: Potential side effects
Hoyer, D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108233 · Cited by 43
Stereochemical analysis of 3,4‐methylenedioxymethamphetamine and its main metabolites by gas chromatography/mass spectrometry
Pizarro, N., Llebaria, A., Cano, S., Joglar, J., Farré, M., Segura, J., & de la Torre, R. (2003) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.919 · Cited by 42
Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy
Oeri, H. E. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120920420 · Cited by 43
Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task
Roberts, G. M. P., Nestor, L. J., & Garavan, H. (2009) · Brain Research · doi:10.1016/j.brainres.2009.07.040 · Cited by 40
Mephedrone and MDMA: A comparative review
Mead, J., & Parrott, A. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146740 · Cited by 39
Cardiac effects of MDMA on the metabolic profile determined with 1H‐magnetic resonance spectroscopy in the rat
Perrine, S. A., Michaels, M. S., Ghoddoussi, F., Hyde, E., Tancer, M. E., & Galloway, M. P. (2008) · NMR in Biomedicine · doi:10.1002/nbm.1352 · Cited by 39
Perspectives on genetic animal models of serotonin toxicity
Kalueff, A. V., LaPorte, J. L., & Murphy, D. L. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.08.015 · Cited by 37
Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?
Gouzoulis‐Mayfrank, E., Becker, S., Pelz, S., Tuchtenhagen, F., & Daumann, J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01306-3 · Cited by 36
Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self‐rated aggression and somatic symptoms
Milani, R. M., Parrott, A. C., Schifano, F., & Turner, J. J. (2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.684 · Cited by 36
The many faces of ecstasy
Doyon, S. (2001) · Current Opinion in Pediatrics · doi:10.1097/00008480-200104000-00015 · Cited by 34
Self reported sleep quality and cognitive performance in ecstasy users
Montgomery, C., Fisk, J. E., Wareing, M., & Murphy, P. N. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.879 · Cited by 32
Ecstasy (MDMA) exposure and neuropsychological functioning: A polydrug perspective
Lisdahl, K. M., Shear, P. K., & Corcoran, K. J. (2005) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617705050915 · Cited by 31
The Effect of Catecholamine Depletion by Alpha-Methyl-Para-Tyrosine on Measures of Cognitive Performance and Sleep in Abstinent MDMA Users
McCann, U. D., Peterson, S., & Ricaurte, G. A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301302 · Cited by 31
Self-citation
Impaired perception of self-motion (heading) in abstinent ecstasy and marijuana users
Rizzo, M., Lamers, C. T. J., Sauer, C. G., Ramaekers, J. G., Bechara, A., & Andersen, G. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2100-7 · Cited by 30
Assessing long-term effects of MDMA (Ecstasy)
Ricaurte, G. A., & McCann, U. D. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06880-5 · Cited by 30
Self-citation
Stimulants, ecstasy, and other ‘party drugs’
WINSTOCK, A. R., & Flechais, R. (2020) · doi:10.1093/med/9780198713005.003.0053 · Cited by 29
Designer drugs in the general hospital
Bialer, P. A. (2002) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(03)00060-1 · Cited by 29
MDMA is certainly damaging after 25 years of empirical research: a reply and refutation of Doblinet al. (2014)
Parrott, A. C. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2390 · Cited by 27
Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage
Costa, G., Morelli, M., & Simola, N. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9761-6 · Cited by 26
Gas chromatography–ion trap mass spectrometry method for the simultaneous measurement of MDMA (ecstasy) and its metabolites, MDA, HMA, and HMMA in plasma and urine
Gomes, D., de Pinho, P. G., Pontes, H., Ferreira, L. M., Branco, P. S., Remião, F., Carvalho, F. D., Bastos, M. D. L., & Carmo, H. (2010) · Journal of Chromatography B · doi:10.1016/j.jchromb.2010.01.042 · Cited by 26
Current and former ecstasy users report different sleep to matched controls: a web-based questionnaire study
Carhart-Harris, R. L., Nutt, D., Munafo, M. R., & Wilson, S. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089599 · Cited by 25
Long-term effects of MDMA (Ecstasy) on the human central nervous system revealed by visual evoked potentials
Casco, C., Forcella, M., Beretta, G., Grieco, A., & Campana, G. (2005) · Addiction Biology · doi:10.1080/13556210500123340 · Cited by 22
Widespread reduction of dopamine cell bodies and terminals in adult rats exposed to a low dose regimen of MDMA during adolescence
Cadoni, C., Pisanu, A., Simola, N., Frau, L., Porceddu, P. F., Corongiu, S., Dessì, C., Sil, A., Plumitallo, A., Wardas, J., et al. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.06.008 · Cited by 20

Authors: McCann, U. D., Eligulashvili, V., & Ricaurte, G. A.
Affiliations: Johns Hopkins University (US)
Venue: Neuropsychobiology
Publisher: S. Karger AG
Published: 2000
Volume: 42
Issue: 1
Pages: 11-16
ISSN: 0302-282X (ISSN-L)
1423-0224
DOI: 10.1159/000026665
OpenAlex: W2056429846
Cited by: 190
References: 36
Citations by year: 2026: 1 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 7 · 2019: 1 · 2018: 1 · 2017: 7 · 2016: 1 · 2015: 2 · 2014: 9 · 2013: 2 · 2012: 4
FWCI: 20.20
Type: journal article
Language: en
Open access: closed
Licence: www.karger.com/Services/SiteLicenses (vor)
www.karger.com/Services/SiteLicenses (tdm)
Locations: Neuropsychobiology (publishedVersion)
PubMed (publishedVersion)
Funders: Johns Hopkins University
Deutsches Krebsforschungszentrum
National Institute on Drug Abuse (DA05938, DA05707, DA 00206, R01DA005938)
NIH Clinical Center
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Keywords: MDMA, ecstasy, serotonin neurotoxicity, recreational drug use, 5-hydroxyindoleacetic acid, serotonin transporter, cognitive impairment, sleep architecture, impulsivity, neuropsychiatric disorders
MeSH terms: Animals, Hallucinogens, Humans, Serotonin, Serotonin Agents, N-Methyl-3,4-methylenedioxyamphetamine, Neurotoxicity Syndromes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks